192 related articles for article (PubMed ID: 32037284)
1. The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial.
van der Werf A; Langius JAE; Beeker A; Ten Tije AJ; Vulink AJ; Haringhuizen A; Berkhof J; van der Vliet HJ; Verheul HMW; de van der Schueren MAE
Clin Nutr; 2020 Oct; 39(10):3005-3013. PubMed ID: 32037284
[TBL] [Abstract][Full Text] [Related]
2. The effect of individualized nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: a randomized controlled trial protocol.
van der Werf A; Blauwhoff-Buskermolen S; Langius JA; Berkhof J; Verheul HM; de van der Schueren MA
BMC Cancer; 2015 Mar; 15():98. PubMed ID: 25884881
[TBL] [Abstract][Full Text] [Related]
3. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
Antoun S; Bayar MA; Dyevre V; Lanoy E; Smolenschi C; Ducreux M
BMC Cancer; 2019 Aug; 19(1):847. PubMed ID: 31462288
[TBL] [Abstract][Full Text] [Related]
4. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
5. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis.
Rinninella E; Cintoni M; Raoul P; Pozzo C; Strippoli A; Bria E; Tortora G; Gasbarrini A; Mele MC
Clin Nutr; 2020 Jul; 39(7):2045-2054. PubMed ID: 31718876
[TBL] [Abstract][Full Text] [Related]
6. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
7. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
[TBL] [Abstract][Full Text] [Related]
9. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
[TBL] [Abstract][Full Text] [Related]
10. Physical performance has a strong association with poor surgical outcome in older patients with colorectal cancer.
Souwer ET; Moos SI; van Rooden CJ; Bijlsma AY; Bastiaannet E; Steup WH; Dekker JWT; Fiocco M; van den Bos F; Portielje JE
Eur J Surg Oncol; 2020 Mar; 46(3):462-469. PubMed ID: 31899045
[TBL] [Abstract][Full Text] [Related]
11. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
[TBL] [Abstract][Full Text] [Related]
12. Impact of oral nutritional supplements in post-discharge patients at nutritional risk following colorectal cancer surgery: A randomised clinical trial.
Tan S; Meng Q; Jiang Y; Zhuang Q; Xi Q; Xu J; Zhao J; Sui X; Wu G
Clin Nutr; 2021 Jan; 40(1):47-53. PubMed ID: 32563599
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study.
Mazzuca F; Roberto M; Arrivi G; Sarfati E; Schipilliti FM; Crimini E; Botticelli A; Di Girolamo M; Muscaritoli M; Marchetti P
Integr Cancer Ther; 2019; 18():1534735419866920. PubMed ID: 31370717
[No Abstract] [Full Text] [Related]
16. Nutritional support in patients with colorectal cancer during chemotherapy: does it work?
Dobrila-Dintinjana R; Trivanovic D; Zelić M; Radić M; Dintinjana M; Petranović D; Toni V; Vukelic J; Matijasic N
Hepatogastroenterology; 2013 May; 60(123):475-80. PubMed ID: 23108082
[TBL] [Abstract][Full Text] [Related]
17. Impact of low skeletal muscle mass and density on short and long-term outcome after resection of stage I-III colorectal cancer.
van Vugt JLA; Coebergh van den Braak RRJ; Lalmahomed ZS; Vrijland WW; Dekker JWT; Zimmerman DDE; Vles WJ; Coene PLO; IJzermans JNM
Eur J Surg Oncol; 2018 Sep; 44(9):1354-1360. PubMed ID: 29914788
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
[TBL] [Abstract][Full Text] [Related]
20. Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Tzeng CD; Chun YS; Lee JE; Vauthey JN; Aloia TA; Conrad C
Surgery; 2019 Feb; 165(2):329-336. PubMed ID: 30197278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
